From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
AngiotensinII (AngiotensinII) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human also induces apoptosis. AngiotensinII induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII human (AngiotensinII) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human acetate also induces apoptosis. AngiotensinII human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human TFA also induces apoptosis. AngiotensinII human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII antipeptide, a peptide, is an inverse agonist of AR1 receptor. AngiotensinII antipeptide is encoded by mRNA, complementary to that encoding AngiotensinII (HY-13948) itself .
AngiotensinII (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensinII . AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
AngiotensinII (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
AngiotensinII (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
[Sar1, Ile8]-AngiotensinII (TFA) is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
AngiotensinII human- 13C6, 15N TFA (Ang II- 13C6, 15N TFA) is 13C- and 15N-labeled AngiotensinII human (TFA) (HY-13948B). AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions .
Angiotensin amide ((Asn1,Val5)-AngiotensinII) is a potent vasoconstrictor. Angiotensin amide is a derivative of angiotensinII. Angiotensin amide can be used as a cardiac activator .
(Sar1)-AngiotensinII, an analogue of AngiotensinII, is a specific agonist of angiotensin AT1 receptor. (Sar1)-AngiotensinII binds to brain membrane-rich particles, with a Kd of 2.7 nM. (Sar1)-AngiotensinII can stimulate protein synthesis and cell growth in embryonic chick myocytes .
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. AngiotensinII is produced from angiotensin I. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensinII. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. AngiotensinII is produced from angiotensin I. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensinII. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
(Sar1,Ile4,8)-AngiotensinII is a functionally selective angiotensinII type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
Saralasin ([Sar1,Ala8] AngiotensinII) acetate hydrate is an octapeptide analog of angiotensinII. Saralasin acetate hydrate is a competitive angiotensinII receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Saralasin ([Sar1,Ala8] AngiotensinII) is an octapeptide analog of angiotensinII. Saralasin is a competitive angiotensinII receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
[Sar1, Ile8]-AngiotensinII is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
Saralasin ([Sar1,Ala8] AngiotensinII) TFA is an octapeptide analog of angiotensinII. Saralasin TFA is a competitive angiotensinII receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Angiotensin-converting enzyme (ACE) is a dicarboxypeptidase, it converts inactive Angiotensin I (Ang I) to active Ang II and degrades active bradykinin (BK). Angiotensin-converting enzyme is a potent vasoconstrictor, is often used in biochemical studies .
[Tyr(P)4] AngiotensinII is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels .
Azilsartan medoxomil (TAK 491) is an orally administered angiotensinII receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension .
Antihypertensive agent 2 (Compound 4g) is an antihypertensive agent. Antihypertensive agent 2 has effective antagonistic activities against angiotensinII receptor 1. Antihypertensive agent 2 reduces the blood pressure with equal or more potency compared to Losartan (HY-17512) .
Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensinII receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensinII-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure .
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and angiotensinII receptor blocker, with IC50s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .
Candesartan (CV 11974) is an orally active angiotensinII AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
Azilsartan mepixetil is the antagonist of angiotensinII receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
Losartan potassium (DuP-753 potassium) is an angiotensinII receptor type 1 (AT1) antagonist, competing with the binding of angiotensinII to AT1 with an IC50 of 20 nM.
Losartan-d4 is the deuterium labeled Losartan. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d3 Carboxylic Acid is the deuterium labeled Losartan. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d2 is the deuterium labeled Losartan[1]. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d9 is the deuterium labeled Losartan[1]. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Biotinyl-Angiotensin I (human, mouse, rat) is biotin-labeled Angiotensin I . Angiotensin I (human, mouse, rat) is the precursor to the vasoconstrictor peptide angiotensinII, cleaved by the angiotensin-converting enzyme (ACE) .
Losartan (potassium) (Standard) is the analytical standard of Losartan (potassium). This product is intended for research and analytical applications. Losartan potassium (DuP-753 potassium) is an angiotensinII receptor type 1 (AT1) antagonist, competing with the binding of angiotensinII to AT1 with an IC50 of 20 nM.
Enalaprilat dihydrate (MK-422), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat dihydrate can be used for the research of hypertension .
Enalaprilat (MK-422 anhydrous), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat can be used for the research of hypertension .
Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active angiotensinII receptor antagonist, used as an antihypertensive. Eprosartan mesylate binds angiotensinII receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
Quinaprilat hydrate is a non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrate specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensinII and inhibits the degradation of bradykinin. Quinaprilat hydrate acts as anti-hypertensive agent and vasodilator .
Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensinII. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers .
Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensinII receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensinII receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
Quinaprilat is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensinII and inhibits the degradation of bradykinin. Quinaprilat acts as anti-hypertensive agent and vasodilator .
Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensinII. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure .
Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensinII. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure .
Eprosartan-d3 is the deuterium labeled Eprosartan. Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensinII receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensinII receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively [1].
Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensinII receptor antagonist for the treatment of high blood pressure and heart failure .
Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits AngiotensinII (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
Eprosartan (mesylate) (Standard) is the analytical standard of Eprosartan (mesylate). This product is intended for research and analytical applications. Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active angiotensinII receptor antagonist, used as an antihypertensive. Eprosartan mesylate binds angiotensinII receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits AngiotensinII (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
Imidapril hydrochloride (TA-6366) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril hydrochloride suppresses the conversion of angiotensin I to angiotensinII and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril hydrochloride can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research .
Imidapril (TA-6366 free base) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril suppresses the conversion of angiotensin I to angiotensinII and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research .
Deserpidine (Harmonyl) is an alkaloid isolated from the root of Rauwolfia canescens related to Reserpine. Deserpidine is used as an antihypertensive agent and a tranquilizer. Deserpidine is a competitive angiotensin converting enzyme (ACE) inhibitor. Deserpidine also decreases angiotensinII-induced aldosterone secretion by the adrenal cortex .
Azilsartan medoxomil monopotassium is an orally administered angiotensinII receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.
Dehydro Olmesartan is a derivative of Olmesartan. Olmesartan is an angiotensinII receptor (AT1R) antagonist and has the potential for high blood pressure study .
CAY 10434 is a potent CYP4A hydroxylase inhibitor. CAY 10434 improves contractile response to angiotensinII with the maximal contractile response (Emax) 6764 mg .
Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats .
EMD 66684 is an antagonist of AngiotensinII Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant - .
Irbesartan-d6 is the deuterium labeled Irbesartan. Irbesartan is a highly potent and specific angiotensinII type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Olmesartan lactone impurity is a cyclic ester impurity of Olmesartan. Olmesartan is an angiotensinII receptor (AT1R) antagonist and has the potential for high blood pressure study .
Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Antihypertensive agent 3 (compound 4a) is an antagonis of angiotensinII receptor 1. Antihypertensive agent 3 exhibits antihypertensive activity in a spontaneously hypertensive rats (SHRs) model .
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
Quinaprilat-d5 is a deuterium-labeled Quinaprilat. Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensinII and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance[1].
Olmesartan impurity is an Olmesartan impurity. Olmesartan (RNH-6270) is an angiotensinII receptor (AT1R) antagonist has the potential for high blood pressure study .
Olmesartan ethyl ester (compound 11) is an Olmesartan impurity. Olmesartan (RNH-6270) is an angiotensinII receptor (AT1R) antagonist used to in the high blood pressure study .
Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class III isoenzyme, inhibits cerebrovascular angiotensinII-dependent and -independent AT1 receptor responses .
(Rac)-Valsartan-d9 is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[1].
NO-Losartan A (compound 2a) displays vasorelaxing effects, due to the release of NO, and antagonized the vasocontractile effects of AngiotensinII (HY-13948), with potency values similar to that of Losartan (HY-17512) .
Benzyl benzoate (Phenylmethyl benzoate) is an orally active anti-scabies agent, acaricide (EC50= 0.06 g/m 2) and fungicide. Benzyl benzoate is an angiotensinII (Ang II) inhibitor with antihypertensive effects. Benzyl benzoate can be used in perfumes, pharmaceuticals and the food industry .
TRV055, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinII receptor type 1 (AT1R). TRV055 is efficacious in stimulating cellular Gq-mediated signaling .
TRV055 hydrochloride, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinII receptor type 1 (AT1R). TRV055 hydrochloride is efficacious in stimulating cellular Gq-mediated signaling .
Valsartan-d3 is the deuterium labeled Valsartan[1]. Valsartan (CGP 48933) is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[2].
Valsartan (Standard) is the analytical standard of Valsartan. This product is intended for research and analytical applications. Valsartan (CGP 48933) is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research .
Sparsentan-d5 is deuterium labeled Sparsentan. Sparsentan (RE-021) is a highly potent dual angiotensinII and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively[1].
Buloxibutid (AT2 receptor agonist C21) is a agentlike selective angiotensinII AT2 receptor agonist with Ki values of 0.4 nM and >10 μM for the AT2 receptor and AT1 receptor, respectively .
TD-0212 TFA is an orally active dual pharmacology angiotensinII type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP .
Losartan carboxylic acid-d4 (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensinII receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensinII-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].
TD-0212 (compound 35) is an orally active dual pharmacology angiotensinII type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP .
15-Keto-PGA1 is a metabolite of PGA1 and has significant vasoconstrictive effects. PGA1 is also a vasoconstrictor and is more potent than equivalent doses of prostaglandin F2α (PGF2α) and angiotensinII .
Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of AngiotensinII Type 1. Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organs .
Olmesartan-d6 (RNH-6270-d6) is the deuterium labeled Olmesartan. Olmesartan (RNH-6270) is an angiotensinII receptor (AT1R) antagonist used to treat high blood pressure[1][2].
BMS-248360 is a potent and orally active dual antagonist of both angiotensinII receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 displays hypertensive effects .
TRV056 is a Gq-biased ligand of the angiotensinII receptor type 1 (AT1R). TRV056 is efficacious in stimulating cellular Gq-mediated signaling. TRV056 can be used to develop the Gq-biased AT1R agonists .
GSK1820795A, as a telmisartan analog, is a selective hGPR132a antagonist. GSK1820795A blocks activation of yeast cells expressing hGPR132a by N-acylamides . GSK1820795A is also a angiotensinII antagonists and partial PPARγ agonists (compound 38) .
Candesartan Cilexetil (TCV-116) is an angiotensinII receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .
Telmisartan (Standard) is the analytical standard of Telmisartan. This product is intended for research and analytical applications. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Telmisartan-d4 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
Telmisartan-d3 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
Telmisartan- 13C,d3 is the 13C- and deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensinII receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .
TRV120027, a β-arrestin-1-biased agonist of the angiotensinII receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model .
Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects . Tranilast sodium antagonizes angiotensinII and inhibits its biological effects in vascular smooth muscle cells .
Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensinII type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research .
Telmisartan-d7 (BIBR 277-d7) is a deuterium labeled Telmisartan (HY-13955). Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensinII (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors .
YS-49 (monohydrate) is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensinII (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors .
Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensinII receptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
Candesartan Cilexetil (Standard) is the analytical standard of Candesartan Cilexetil. This product is intended for research and analytical applications. Candesartan Cilexetil (TCV-116) is an angiotensinII receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
Azilsartan-d4 is the deuterium labeled Azilsartan[1]. Azilsartan is an orally active, potent, selective and specific angiotensinII type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research[2][3][4][5][6].
Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensinII AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
(Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity .
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
AT2R antagonist 1 (compound 21) is a potent and high selective AT2R (angiotensinII AT2 receptor) ligand. AT2R antagonist 1 exhibits a fair AT2R affinity, with a Ki of 29 nM. AT2R antagonist 1 also inhibits common agent-metabolizing CYP enzymes. AT2R antagonist 1 shows high stability in human, rat and mouse liver microsomes .
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensinII-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .
Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensinII type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .
Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis .
Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is an antagonist of angiotensinII receptor (IC50=48.2 μM). Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is a quinolone alkaloid from Evodia rutaecarpa .
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensinII type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .
AT2 receptor ligand-1(compound 14) is a potent angiotensin AT2 receptor ligand with the Ki 4.9 nM. AT2 receptor ligand-1 shows high stability in microsomes of the sulfonamide ligands .
Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects - .
Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects - .
Angiotensin-converting enzyme (ACE) is a dicarboxypeptidase, it converts inactive Angiotensin I (Ang I) to active Ang II and degrades active bradykinin (BK). Angiotensin-converting enzyme is a potent vasoconstrictor, is often used in biochemical studies .
Chymase is a protein-digester enzyme found primarily in mast cells (MC), fibroblasts, and vascular endothelial cells. Chymase is released into the extracellular stroma in the context of inflammatory signals, tissue injury and cellular stress. Chymase is also involved in angiotensinII (Ang II) production, which is used in cardiovascular disease studies .
AngiotensinII (AngiotensinII) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human also induces apoptosis. AngiotensinII induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII human (AngiotensinII) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human acetate also induces apoptosis. AngiotensinII human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human TFA also induces apoptosis. AngiotensinII human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
AngiotensinII antipeptide, a peptide, is an inverse agonist of AR1 receptor. AngiotensinII antipeptide is encoded by mRNA, complementary to that encoding AngiotensinII (HY-13948) itself .
AngiotensinII (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensinII . AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
AngiotensinII human, FAM-labeled (AngiotensinII, FAM-labeled ; Ang II, FAM-labeled ; DRVYIHPF, FAM-labeled) is a biological active peptide. (FAM labeled HY-13948)
AngiotensinII (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
AngiotensinII (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). AngiotensinII binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. AngiotensinII also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
[Sar1, Ile8]-AngiotensinII (TFA) is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
Angiotensin amide ((Asn1,Val5)-AngiotensinII) is a potent vasoconstrictor. Angiotensin amide is a derivative of angiotensinII. Angiotensin amide can be used as a cardiac activator .
(Sar1)-AngiotensinII, an analogue of AngiotensinII, is a specific agonist of angiotensin AT1 receptor. (Sar1)-AngiotensinII binds to brain membrane-rich particles, with a Kd of 2.7 nM. (Sar1)-AngiotensinII can stimulate protein synthesis and cell growth in embryonic chick myocytes .
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. AngiotensinII is produced from angiotensin I. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensinII. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. AngiotensinII is produced from angiotensin I. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensinII. AngiotensinII has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .
Biotin-Ahx-AngiotensinII human (Biotin-Ahx-AngiotensinII; Biotin-Ahx-Ang II; Biotin-Ahx-DRVYIHPF) is a biological active peptide. (biotin labeled HY-13948)
(Sar1,Ile4,8)-AngiotensinII is a functionally selective angiotensinII type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-AngiotensinII potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
Saralasin ([Sar1,Ala8] AngiotensinII) acetate hydrate is an octapeptide analog of angiotensinII. Saralasin acetate hydrate is a competitive angiotensinII receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
[Sar1, Ile8]-AngiotensinII is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
Saralasin ([Sar1,Ala8] AngiotensinII) TFA is an octapeptide analog of angiotensinII. Saralasin TFA is a competitive angiotensinII receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .
Angiotensin-converting enzyme (ACE) is a dicarboxypeptidase, it converts inactive Angiotensin I (Ang I) to active Ang II and degrades active bradykinin (BK). Angiotensin-converting enzyme is a potent vasoconstrictor, is often used in biochemical studies .
[Tyr(P)4] AngiotensinII is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels .
Biotinyl-Angiotensin I (human, mouse, rat) is biotin-labeled Angiotensin I . Angiotensin I (human, mouse, rat) is the precursor to the vasoconstrictor peptide angiotensinII, cleaved by the angiotensin-converting enzyme (ACE) .
5-Valine-angiotensin I is an Ang I peptide belonging to angiotensin I. 5-Valine-angiotensin I induces muscle contraction, can be used for renin-angiotensin system studies. Angiotensin I is a putative neurotransmitter, is the precursor of angiotensinII and of angiotensin fragment 1-7, which are involved in regulation of fluid volume and the release of aldosterone .
Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensinII. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers .
Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits AngiotensinII (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits AngiotensinII (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
TRV055, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinII receptor type 1 (AT1R). TRV055 is efficacious in stimulating cellular Gq-mediated signaling .
TRV055 hydrochloride, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensinII receptor type 1 (AT1R). TRV055 hydrochloride is efficacious in stimulating cellular Gq-mediated signaling .
TRV056 is a Gq-biased ligand of the angiotensinII receptor type 1 (AT1R). TRV056 is efficacious in stimulating cellular Gq-mediated signaling. TRV056 can be used to develop the Gq-biased AT1R agonists .
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensinII receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .
TRV120027, a β-arrestin-1-biased agonist of the angiotensinII receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensinII–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensinII protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
AngiotensinII (AngiotensinII) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. AngiotensinII human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. AngiotensinII human also induces apoptosis. AngiotensinII induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
Deserpidine (Harmonyl) is an alkaloid isolated from the root of Rauwolfia canescens related to Reserpine. Deserpidine is used as an antihypertensive agent and a tranquilizer. Deserpidine is a competitive angiotensin converting enzyme (ACE) inhibitor. Deserpidine also decreases angiotensinII-induced aldosterone secretion by the adrenal cortex .
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, a quinolone alkaloid, is a diacylglycerol acyltransferase inhibitor and angiotensinII receptor blocker, with IC50s of 20.1 μM and 34.1 μM, respectively. 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone shows potent anti-Helicobacter pylori activity with the MIC of 10 μg/mL .
Benzyl benzoate (Phenylmethyl benzoate) is an orally active anti-scabies agent, acaricide (EC50= 0.06 g/m 2) and fungicide. Benzyl benzoate is an angiotensinII (Ang II) inhibitor with antihypertensive effects. Benzyl benzoate can be used in perfumes, pharmaceuticals and the food industry .
Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is an antagonist of angiotensinII receptor (IC50=48.2 μM). Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is a quinolone alkaloid from Evodia rutaecarpa .
The NLRP6 protein serves as the central sensor of the NLRP6 inflammasome, driving inflammasome activation in response to various pathogen-related signals. It recognizes specific pathogen- and damage-associated signals, such as lipoteichoic acid (LTA) and double-stranded RNA (dsRNA), initiating liquid-liquid phase separation (LLPS) to form complexes. NLRP6 Protein, Human (Sf9) is the recombinant human-derived NLRP6 protein, expressed by Sf9 insect cells , with tag free. The total length of NLRP6 Protein, Human (Sf9) is 892 a.a., .
Serpin A8/angiotensinogen protein is an important component of the renin-angiotensin system (RAS), which regulates blood pressure, fluid balance, and electrolyte homeostasis. Serpin A8/Angiotensinogen Protein, Human (HEK293, His, solution) is the recombinant human-derived Serpin A8/Angiotensinogen protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Serpin A8/Angiotensinogen Protein, Human (HEK293, His, solution) is 452 a.a., with molecular weight of 55.0-72.27 kDa.
Serpin A8 (or angiotensinogen) is a key regulator of the renin-angiotensin system, affecting blood pressure, fluid and electrolyte balance. As a vasoconstrictor, it directly affects vascular smooth muscle and affects myocardial contractility and heart rate through the sympathetic nervous system. Serpin A8/Angiotensinogen Protein, Rat (HEK293, His) is the recombinant rat-derived Serpin A8/Angiotensinogen protein, expressed by HEK293 , with C-His labeled tag. The total length of Serpin A8/Angiotensinogen Protein, Rat (HEK293, His) is 453 a.a., with molecular weight of 58-75 kDa.
Serpin A8 (or angiotensinogen) is an important regulator in the renin-angiotensin system, fine-tuning blood pressure and electrolyte balance. This multifunctional protein acts as a potent vasoconstrictor, affecting vascular smooth muscle and affecting cardiac function via the sympathetic nervous system. Serpin A8/Angiotensinogen Protein, Mouse (HEK293, His) is the recombinant mouse-derived Serpin A8/Angiotensinogen protein, expressed by HEK293 , with C-His labeled tag. The total length of Serpin A8/Angiotensinogen Protein, Mouse (HEK293, His) is 453 a.a., with molecular weight of ~58 kDa.
Serpin A8/angiotensinogen protein is an important component of the renin-angiotensin system (RAS), which regulates blood pressure, fluid balance, and electrolyte homeostasis. Serpin A8/Angiotensinogen Protein, Human (HEK293, His) is the recombinant human-derived Serpin A8/Angiotensinogen protein, expressed by HEK293 , with C-His labeled tag. The total length of Serpin A8/Angiotensinogen Protein, Human (HEK293, His) is 452 a.a., with molecular weight of 52-64 kDa.
AngiotensinII human- 13C6, 15N TFA (Ang II- 13C6, 15N TFA) is 13C- and 15N-labeled AngiotensinII human (TFA) (HY-13948B). AngiotensinII human (AngiotensinII) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. AngiotensinII human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngiotensinII and the G-protein-coupled receptors (GPCRs) AngiotensinII type 1 receptor (AT1R) and AngiotensinII type 2 receptor (AT2R). AngiotensinII human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions .
Losartan-d4 is the deuterium labeled Losartan. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d3 Carboxylic Acid is the deuterium labeled Losartan. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d2 is the deuterium labeled Losartan[1]. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Losartan-d9 is the deuterium labeled Losartan[1]. Losartan is an angiotensinII receptor antagonist, competing with the binding of angiotensinII to AT1 receptors with IC50 of 20 nM.
Eprosartan-d3 is the deuterium labeled Eprosartan. Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensinII receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensinII receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively [1].
Irbesartan-d6 is the deuterium labeled Irbesartan. Irbesartan is a highly potent and specific angiotensinII type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.
Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Quinaprilat-d5 is a deuterium-labeled Quinaprilat. Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensinII and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance[1].
Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[1].
(Rac)-Valsartan-d9 is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Valsartan-d3 is the deuterium labeled Valsartan[1]. Valsartan (CGP 48933) is an angiotensinII receptor antagonist and has the potential for high blood pressure and heart failure research[2].
Sparsentan-d5 is deuterium labeled Sparsentan. Sparsentan (RE-021) is a highly potent dual angiotensinII and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively[1].
Losartan carboxylic acid-d4 (hydrochloride) is deuterium labeled Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensinII receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensinII-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure[1][2][3][4].
Olmesartan-d6 (RNH-6270-d6) is the deuterium labeled Olmesartan. Olmesartan (RNH-6270) is an angiotensinII receptor (AT1R) antagonist used to treat high blood pressure[1][2].
Telmisartan-d4 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
Telmisartan-d3 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
Telmisartan- 13C,d3 is the 13C- and deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Telmisartan-d7 (BIBR 277-d7) is a deuterium labeled Telmisartan (HY-13955). Telmisartan is a potent, long lasting antagonist of angiotensinII type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Azilsartan-d4 is the deuterium labeled Azilsartan[1]. Azilsartan is an orally active, potent, selective and specific angiotensinII type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research[2][3][4][5][6].
ACE Antibody is an unconjugated, approximately 147 kDa, rabbit-derived, anti-ACE polyclonal antibody. ACE Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, rat, and predicted: dog, pig, cow, sheep background without labeling.
Inquiry Online
Your information is safe with us. * Required Fields.